Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KTd vs KRd Induction and Carfilzomib Maintenance in NDMM
NCT02891811Phase 2Completed
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Start
- Mar 2017
- Primary completion
- Mar 2024
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of carfilzomib in multiple myeloma (MM) (4 arms), sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Primary endpoint: Overall Response Rate at 36 weeks. Started Mar 2017; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02891811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02891811.